Aspirin Dosing and Platelet Phenotype in Pregnancy
NYU Langone Health
Summary
The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Eligibility
- Age range
- 18–50 years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: * Pregnant people prior to 17 weeks * Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates * Age 18-50 years * Singleton viable gestation * Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors. Exclusion Criteria: * Undergoing glucose challenge test (GCT) at time of blood draw * Allergy or intolerance to aspirin * Antithrombotic or antiplatelet therapy * Anemia (hemoglobin \<10 g/dl) or thrombocytopenia (platelet count \<100,000), or thrombocytosi…
Interventions
- DrugAspirin
81mg twice a day (162mg total)
Location
- NYU Langone HealthNew York, New York